In phase I(safety) trials, we have demonstrated the feasibility of autologo
us hematopoietic stem cell transplantation (HSCT) for patients with autoimm
une diseases. Although this review comments on results of our phase I trial
s, the focus is on phase II (efficacy) trials using gene-marked autologous
stem cells.